Tier 3 — preclinical
A reduced form of nicotinamide riboside defines a new path for NAD + biosynthesis and acts as an orally bioavailable NAD + precursor
Molecular metabolism
2019
30; 192-202
Bibliography
- PubMed
- PMID 31767171
- PubMed Central
- PMC6807296
- Funding
- Funding/support listed in the publication: Ecole Polytechnique Fédérale de Lausanne (EPFL); Nestlé Research Ltd; EU Marie Sklodowska-Curie ITN-ChroMe; European Union’s Horizon 2020; Fundación Séneca - Agencia de Ciencia y Tecnología de la Región de Murcia; NIH.
- Competing interests
- A complete competing-interest declaration is not specified in the accessible publication information.
Study snapshot
| Design | Preclinical animal study with supporting assays as applicable |
|---|---|
| Model | Mammalian cells and mice |
| Sample | Mammalian cells and mice |
| Intervention | Reduced nicotinamide riboside (NRH), compared with NR |
| Duration | Cell experiments and acute mouse exposure |
| Endpoints | Model-specific physiological outcomes; Biochemical or functional measures reported in the study |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
